See more : Lithium Chile Inc. (LITH.V) Income Statement Analysis – Financial Results
Complete financial analysis of eFFECTOR Therapeutics, Inc. (EFTR) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of eFFECTOR Therapeutics, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- PCCW Limited (PCWLF) Income Statement Analysis – Financial Results
- EQM Technologies & Energy, Inc. (EQTE) Income Statement Analysis – Financial Results
- Tianjin Printronics Circuit Corporation (002134.SZ) Income Statement Analysis – Financial Results
- JSW Holdings Limited (JSWHL.BO) Income Statement Analysis – Financial Results
- Snap Inc. (1SI.DE) Income Statement Analysis – Financial Results
eFFECTOR Therapeutics, Inc. (EFTR)
About eFFECTOR Therapeutics, Inc.
eFFECTOR Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of selective translation regulator inhibitors for the treatment of cancer. Its lead product candidate is Tomivosertib, an oral small-molecule inhibitor of MNK that is in phase 2b clinical trial for the treatment of patients with metastatic non-small cell lung cancer. The company is also developing Zotatifin, a small molecule designed to inhibit eukaryotic initiation factor 4A (eIF4E), which is in phase 2clinical trial to treat patients with solid tumors. It has a collaboration agreement with Pfizer Inc. to develop inhibitors of eIF4E. eFFECTOR Therapeutics, Inc. was founded in 2012 and is headquartered in Solana Beach, California.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|
| Revenue | 0.00 | 3.55M | 1.43M | 42.00M | 0.00 |
| Cost of Revenue | 22.92M | 53.00K | 24.00K | 21.83M | 307.00K |
| Gross Profit | -22.92M | 3.50M | 1.41M | 20.17M | -307.00K |
| Gross Profit Ratio | 0.00% | 98.51% | 98.32% | 48.02% | 0.00% |
| Research & Development | 22.92M | 23.31M | 19.96M | 21.83M | 23.58M |
| General & Administrative | 10.93M | 12.64M | 13.37M | 4.35M | 4.72M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 10.93M | 12.64M | 13.37M | 4.35M | 4.72M |
| Other Expenses | 0.00 | -3.55M | -1.43M | 9.00K | 0.00 |
| Operating Expenses | 33.84M | 32.40M | 31.90M | 26.18M | 28.30M |
| Cost & Expenses | 33.84M | 32.40M | 31.90M | 26.18M | 28.61M |
| Interest Income | 1.95M | 439.00K | 6.00K | 67.00K | 239.00K |
| Interest Expense | 0.00 | 2.25M | 1.76M | 1.33M | 1.38M |
| Depreciation & Amortization | 111.00K | 53.00K | 24.00K | 160.00K | 307.00K |
| EBITDA | -33.73M | -32.40M | -31.90M | 16.06M | -28.30M |
| EBITDA Ratio | 0.00% | -911.99% | -2,230.56% | 38.23% | 0.00% |
| Operating Income | -33.84M | -32.40M | -31.90M | 15.82M | -28.61M |
| Operating Income Ratio | 0.00% | -911.99% | -2,230.56% | 37.66% | 0.00% |
| Total Other Income/Expenses | -1.97M | 9.74M | 47.70M | -1.26M | -1.13M |
| Income Before Tax | -35.81M | -22.67M | 15.80M | 14.56M | -29.74M |
| Income Before Tax Ratio | 0.00% | -637.91% | 1,104.76% | 34.67% | 0.00% |
| Income Tax Expense | 0.00 | -9.74M | -24.00K | 351.00K | 135.14K |
| Net Income | -35.81M | -12.93M | 15.80M | 14.21M | -29.74M |
| Net Income Ratio | 0.00% | -363.83% | 1,104.76% | 33.84% | 0.00% |
| EPS | -16.37 | -7.85 | 9.78 | 23.74 | -53.83 |
| EPS Diluted | -16.37 | -7.85 | 9.78 | 23.74 | -53.83 |
| Weighted Avg Shares Out | 2.19M | 1.65M | 1.62M | 598.56K | 552.43K |
| Weighted Avg Shares Out (Dil) | 2.19M | 1.65M | 1.62M | 598.56K | 552.43K |
eFFECTOR Therapeutics Reports Third Quarter 2023 Financial Results and Provides Corporate Update
Management intends to provide an update on its zotatifin clinical development program in estrogen receptor-positive (ER+) metastatic breast cancer (mBC) at the 2023 San Antonio Breast Cancer Symposium (SABCS)
eFFECTOR Therapeutics to Participate in Fireside Chat at 2023 Stifel Healthcare Conference
SOLANA BEACH, Calif. and REDWOOD CITY, Calif., Nov. 06, 2023 (GLOBE NEWSWIRE) -- eFFECTOR Therapeutics, Inc. (NASDAQ: EFTR), a leader in the development of selective translation regulator inhibitors (“STRIs”) for the treatment of cancer, today announced that the Company will...
4 Hot Penny Stocks To Watch With Big News This Week
Whether you're trading penny stocks or stocks over $100, the goal is the same. You want to find opportunities as early as possible and capitalize.
eFFECTOR Therapeutics to Collaborate with the Northwestern University Division of Hematology and Oncology on an Investigator-Initiated Phase 1 Dose Escalation Trial Evaluating Tomivosertib in Patients with Acute Myeloid Leukemia
Trial designed to capitalize on previously published results that showed preclinical activity of tomivosertib in AML models Trial designed to capitalize on previously published results that showed preclinical activity of tomivosertib in AML models
3 Promising Biotech Stocks That Will Make Early Investors Rich
For investment ideas that can potentially lead to life-changing gains, few sectors are as viable as biotech stocks to make you rich. Fundamentally, the biotechnology sector offers potential therapeutic innovations that could change paradigms for patient care.
eFFECTOR Therapeutics Appoints Caroline Loewy to Board of Directors
SOLANA BEACH, Calif. and REDWOOD CITY, Calif., Sept. 11, 2023 (GLOBE NEWSWIRE) -- eFFECTOR Therapeutics, Inc. (NASDAQ: EFTR), a leader in the development of selective translation regulator inhibitors (“STRIs”) for the treatment of cancer, today announced the addition of Caroline...
eFFECTOR Therapeutics to Participate in Upcoming Investor Conferences
SOLANA BEACH, Calif. and REDWOOD CITY, Calif., Aug. 30, 2023 (GLOBE NEWSWIRE) -- eFFECTOR Therapeutics, Inc. (NASDAQ: EFTR), a leader in the development of selective translation regulator inhibitors (“STRIs”) for the treatment of cancer, today announced that the management team...
Best Penny Stocks To Buy Now? 10 Under $1 To Watch
The traditional approach to investing is finding well-established companies, investing in them and waiting years for a return of 50%. But in today's fast-paced stock market, retail traders are finding better ways to use the stock market to capture gains.
7 Best Penny Stocks To Buy Under $1 in 2023: Big Risk, Big Return?
Penny stocks, often priced under $1, have long been the allure for many investors seeking high-risk, high-reward opportunities. These stocks, typically from smaller companies, offer the tantalizing possibility of significant returns.
Best Penny Stocks To Buy Under $1.25? 3 To Watch Now
Are you looking for the best penny stocks to buy? You're not alone; many traders are showing a renewed interest in this exciting market.
Source: https://incomestatements.info
Category: Stock Reports